MammaPrint Finds Breast Cancer Patients Who Can Skip Chemo – Medscape
NPR |
MammaPrint Finds Breast Cancer Patients Who Can Skip Chemo
Medscape In breast cancer patients who were judged to be at high risk by clinical assessment, and who were thus destined for chemotherapy, use of the 70-gene signature test (MammaPrint, Agendia) found that half (49%) of these women could skip chemotherapy. When DNA and medical tests disagree about breast cancer risk, which to believe? Study Confirms MammaPrint’s Accuracy in Assessing Treatment for Early Breast Cancer Genomic tools and the era of tailored treatment in breast cancer |
Powered by WPeMatico